<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated distal symmetric polyneuropathy (HIV-DSPN)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated distal symmetric polyneuropathy (HIV-DSPN)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated distal symmetric polyneuropathy (HIV-DSPN)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michelle C Kaku, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Simpson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rajesh T Gandhi, MD, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H486295675">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human immunodeficiency virus (HIV) infection is associated with various peripheral nervous system manifestations, the most common of which is distal symmetric polyneuropathy (DSPN) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Peripheral polyneuropathy should be distinguished from other forms of neuropathy, such as mononeuropathies (focal involvement of a single nerve) and polyradiculopathies (involvement of a nerve root). Other less common peripheral nervous system manifestations in HIV include antiretroviral toxic neuropathy (more common with antiretroviral medications that are no longer widely used), acquired inflammatory demyelinating polyradiculoneuropathy, lumbosacral polyradiculopathy, mononeuropathies, autonomic neuropathy, diffuse infiltrative lymphocytosis syndrome, sensory ganglionopathy, and herpes zoster radiculitis. These entities are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">
          "Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'Acute inflammatory demyelinating polyneuropathy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14149.html" rel="external">
          "Polyradiculopathy: Spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes", section on 'Polyradiculopathy in HIV and AIDS'
         </a>
         .)
        </p>
        <p>
         The epidemiology, pathogenesis, clinical manifestations, diagnosis, and management of patients with HIV-associated DSPN (HIV-DSPN) will be reviewed here.
        </p>
        <p>
         A more generalized approach to a patient with polyneuropathy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">
          "Overview of polyneuropathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5096.html" rel="external">
          "Approach to the patient with sensory loss"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H52056464">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3871462677">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         HIV-DSPN is a common neurologic complication in patients with HIV and can interfere with the patient’s activities of daily living. Reported prevalence rates vary from 1 to 69 percent, with a meta-analysis including over 2000 patients demonstrating a pooled prevalence of 38 percent [
         <a href="#rid2">
          2,3
         </a>
         ]. The wide range is likely attributed to the decreasing prevalence of HIV-DSPN over time due to the early use of more effective and less toxic antiretroviral therapy (ART) and the heterogeneity in the patient population between studies (eg, varying degrees of immunosuppression, differences in exposure to certain antiretrovirals, and varying inclusion criteria of symptomatic versus asymptomatic patients).
        </p>
        <p class="headingAnchor" id="H3312200972">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before the introduction of effective ART, HIV-DSPN was correlated with advanced HIV (lower CD4 count and a higher viral load) [
         <a href="#rid4">
          4,5
         </a>
         ]. However, in the era of effective ART, most studies have not demonstrated this same correlation [
         <a href="#rid6">
          6-9
         </a>
         ]. Viral load has
         <strong>
          not
         </strong>
         been found to be related to HIV-DSPN [
         <a href="#rid8">
          8,10-12
         </a>
         ] and some studies have found a correlation with a higher CD4 count [
         <a href="#rid8">
          8-10,13
         </a>
         ]. In treatment-experienced patients with HIV who have been exposed to older neurotoxic nucleoside reverse transcriptase inhibitors, such as
         <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">
          stavudine
         </a>
         (d4T),
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         (ddI), and zalcitabine (ddC), HIV-DSPN can be complicated by a clinically similar peripheral neuropathy syndrome called antiretroviral toxic neuropathy [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Differential Diagnosis'
         </a>
         below.)
        </p>
        <p>
         Other risk factors not related to HIV include older age, diabetes mellitus, triglyceridemia, statin use, substance use, and taller stature [
         <a href="#rid10">
          10,12,15-19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1899705010">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         HIV-DSPN on histopathology is characterized by distal axonal degradation, neuronal loss in the dorsal root ganglia, and reduced intraepidermal nerve fiber density [
         <a href="#rid20">
          20-25
         </a>
         ]. The pathophysiology of HIV-DSPN is not well understood and is likely a combination of direct and indirect toxic effects on the nerves [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         HIV does not infect cells that lack a CD4 receptor (eg, neurons, dorsal root ganglia, Schwann cells). Virus recovered from nerve tissue is primarily from macrophages and monocytes with relative lack of virus and its infiltrates in the nerve [
         <a href="#rid27">
          27
         </a>
         ]. Therefore, HIV indirectly results in toxic effect through the release of inflammatory cytokines and chemokines from infected monocytes and macrophages [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         However, HIV likely also exerts a direct toxic effect through the envelope glycoprotein gp120. In vitro studies demonstrate that gp120 can bind to rat dorsal root ganglia (DRG) and activate the complement cascade to lyse neuronal cells [
         <a href="#rid29">
          29
         </a>
         ]. Gp120 binds to perineuronal Schwann cells in the DRG via the CXCR4 receptor. This binding leads to aggregation of the CXCR4 receptor and production of the chemokine, RANTES (regulated upon activation, normal T-cell expressed and secreted), which causes neuronal apoptosis via the production of tumor necrosis factor-a [
         <a href="#rid30">
          30
         </a>
         ]. Gp120 has also been found to activate macrophage infiltration, cause neuronal swelling, induce lysosome exocytosis, and release adenosine triphosphate from Schwann cells, leading to an increase in intracellular calcium and cytosolic reactive oxygen species in DRG neurons [
         <a href="#rid31">
          31-33
         </a>
         ].
        </p>
        <p>
         Certain genetic factors may also make patients more at risk for HIV-DSPN. A study of mitochondrial deoxyribonucleic acid (DNA) mutations in human axon samples demonstrated higher levels of mitochondrial DNA deletion mutations in sural nerve specimens of patients with HIV-DSPN compared with patients without HIV-DSPN [
         <a href="#rid34">
          34
         </a>
         ]. Mitochondrial haplotype T is found in people of European descent; a unique single nucleotide polymorphism marker for mitochondrial haplotype T (MTND2*LHON4917G) in the gene encoding a subunit of complex I of the mitochondrial electron transport chain was found to be an independent risk factor for HIV-DSPN in patients of European descent who were on ART [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
         Abnormalities in regenerative and collateral sprouting are also found in patients with HIV [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H961994520">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H825252589">
         <span class="h2">
          Clinical symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Research using nerve conduction studies to assess the prevalence of HIV-DSPN suggests that it is asymptomatic in up to 16 percent of individuals [
         <a href="#rid7">
          7,38
         </a>
         ]. When symptoms are present, HIV-DSPN commonly presents with bilateral tingling, numbness, and burning that start distally in the toes and progress proximally. Over time, the tips of the fingers may become affected; this typically occurs when the level of lower extremity sensory symptoms rises to the knees. Degree of proximal progression varies; one study found that 55 percent have symptoms confined to the feet, 34 percent may have symptoms of neuropathy up to the distal leg, and 11 percent have severe neuropathy that rises to the proximal leg [
         <a href="#rid39">
          39
         </a>
         ]. Patients also often report worsening symptoms with skin contact, such as the weight of sheets on the bed [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Other symptoms and signs suggestive of HIV-DSPN include imbalance and presence of autonomic dysfunction (eg, dizziness or fainting upon standing, urinary retention or incontinence). Symptoms generally progress gradually over the course of several weeks to months.
        </p>
        <p>
         Signs of weakness, rapidly progressive symptoms, or asymmetry are uncommon in HIV-DSPN and are suggestive of a different neuropathic disorder. (See
         <a class="local">
          'Differential Diagnosis'
         </a>
         below.)
        </p>
        <p>
         Severity of neuropathy appears to be related to degree of immunosuppression in addition to other factors. In one study, mean vibratory thresholds were higher in patients with acquired immunodeficiency syndrome (AIDS) compared with patients with asymptomatic HIV [
         <a href="#rid40">
          40
         </a>
         ]. In another study of 251 individuals with HIV-DSPN, neuropathy severity on nerve conduction studies correlated with low CD4 counts, older age, abnormal serum albumin, lower hemoglobin levels, and weight loss [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H868183956">
         <span class="h2">
          Exam features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurologic exam demonstrates a reduction in pinprick, light touch, vibration, and temperature sensation in a stocking-glove distribution. Proprioception is typically unaffected, although up to 20 percent have been found to have reduced or absent proprioception on exam [
         <a href="#rid41">
          41
         </a>
         ]. Ankle reflexes may be reduced or absent. Knee reflexes typically remain intact. Both mild distal weakness and muscle cramping in the lower extremities can occur in more severe neuropathy, although true muscle atrophy is rare [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H373663629">
         <span class="h2">
          Laboratory features
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no specific laboratory features associated with HIV-DSPN. Cerebrospinal fluid (CSF) analysis is not part of the evaluation of HIV-DSPN and is not associated with specific CSF abnormalities, although CSF pleocytosis can be seen in people with untreated HIV infection.
        </p>
        <p class="headingAnchor" id="H3447724333">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         While HIV-DSPN is a clinical diagnosis, identifying and correcting additional reversible causes of neuropathy (eg, diabetic neuropathy, vitamin B12 deficiency) is warranted to optimize nerve function. DSPN can be multi-factorial and all risk factors should be addressed to reduce symptoms and slow disease progression.
        </p>
        <p class="headingAnchor" id="H206610837">
         <span class="h2">
          History and examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of HIV-DSPN should be considered when a patient with HIV presents with distal symmetric neuropathy of the extremities (numbness, tingling, and pain that starts in the feet and may progress proximally). History should include the timing and characteristics of the neuropathy, as well as a review of systems to evaluate for any other potential causes of peripheral neuropathy. Emphasis should be placed on identifying any symptoms and signs of diabetes mellitus, thyroid disorders, kidney and liver disease, connective tissue disorders, and possible nutritional deficiencies (eg, vitamin B12 and folate deficiency). The history should also include potential exposures to various toxins that can induce peripheral neuropathy (eg, heavy alcohol use, medications known to cause neuropathy) as well as a thorough family history to identify any hereditary peripheral neuropathy disorders  (
         <a class="graphic graphic_table graphicRef69751" href="/z/d/graphic/69751.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">
          "Overview of polyneuropathy", section on 'Etiology and pathogenesis'
         </a>
         .)
        </p>
        <p>
         Examination should be comprehensive to evaluate for other potential causes of peripheral neuropathy, as mentioned above. The neurologic exam should include testing the function of light touch, pin prick sensation, temperature sensation, vibration, and joint position sense to differentiate distal symmetric neuropathy from other types of neuropathy (eg, mononeuropathy, radiculopathy). A more detailed discussion on evaluation of polyneuropathy is found elsewhere. (See
         <a class="local">
          'Differential Diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">
          "Overview of polyneuropathy", section on 'Physical examination'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H205376079">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no laboratory studies that specifically point to HIV-DSPN. The role of laboratory testing is to identify other potential causes of peripheral neuropathy. In most cases, the following studies are recommended in the evaluation of peripheral neuropathy in patients with HIV:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood glucose (preferably fasting)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemoglobin A1C
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basic metabolic panel
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum vitamin B12 and folate levels
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum protein electrophoresis with immunofixation, testing of quantitative immunoglobulins, and serum free light chains
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid stimulating hormone
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatitis B and C antibodies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other studies based on risk factors and comorbidities (eg,
         <em>
          B. burgdorferi
         </em>
         serology in patients living in Lyme-endemic areas, antinuclear antibody panel in patients with personal or family history of autoimmune disorders, heavy metal levels in the blood in patients with poor nutrition or appropriate occupational exposure, evaluation for hereditary polyneuropathies in patients with family history of neurologic disease)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1241449682">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases, a typical clinical presentation of a distal sensory neuropathy and exclusion of other causes of peripheral neuropathy in a patient with HIV is sufficient to establish the diagnosis. Occasionally, if the diagnosis is unclear (eg, rapid progression and/or asymmetry of symptoms, presence of weakness), additional testing with nerve conduction study and electromyography may be helpful to further characterize the neuropathy. (See
         <a class="local">
          'Differential Diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1233576260">
         <span class="h2">
          Additional testing in diagnostic uncertainty
         </span>
         <span class="headingEndMark">
          —
         </span>
         In situations where the diagnosis is uncertain, referral to a neurologist for additional testing is warranted. Additional testing to help establish the diagnosis includes nerve conduction study in conjunction with electromyography, skin biopsy, and nerve biopsy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nerve conduction study and electromyography
         </strong>
         − When DSPN is not evident from the history and physical exam, a nerve conduction study and electromyography can be helpful to confirm the presence and type of neuropathy. Nerve conduction studies (NCS) typically demonstrate an axonal sensorimotor polyneuropathy. There is a reduction in the amplitude of sensory and motor action potentials in the lower limbs with normal or reduced nerve conduction velocities [
         <a href="#rid1">
          1,25,38,42
         </a>
         ]. Needle electromyography (EMG) study demonstrates an axonal neuropathy with reduced recruitment with polyphasic potentials in distal leg muscles in severe cases [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin biopsy
         </strong>
         − Skin biopsy is typically reserved for patients in whom there is clear evidence of small fiber neuropathy on physical exam and EMG/NCS are negative for large fiber polyneuropathy. Skin biopsy with protein gene product 9.5 immunostaining demonstrates loss of intraepidermal nerve fiber density (IENFD), often before significant large fiber changes are seen on NCS/EMG and has become the gold standard in evaluating small fiber neuropathy [
         <a href="#rid22">
          22,44,45
         </a>
         ]. The degree of reduction of IENFD correlates with the clinical and electrophysiological severity in patients with HIV-DSPN [
         <a href="#rid22">
          22
         </a>
         ]. In a retrospective study of 67 patients with HIV, increased number of large mitochondrial DNA deletions were associated with loss of IENFD and sural nerve amplitude [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nerve
         </strong>
         <strong>
          biopsy
         </strong>
         − Nerve biopsy is usually not necessary in the evaluation of HIV-DSPN. It is usually reserved for patients in whom mononeuritis multiplex is suspected (eg, asymmetric neuropathic symptoms in the distribution of multiple contiguous nerves) and needs to be ruled out. (See
         <a class="local">
          'Differential Diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3803327708">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of HIV-DSPN includes other conditions associated with progressive distal symmetric polyneuropathy and other similar neuropathies. These include HIV-antiretroviral toxic neuropathy (HIV-ATN), acute inflammatory demyelinating polyradiculoneuropathy (AIDP), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), progressive radiculopathy, and mononeuritis multiplex. Clinical and neurophysiologic features help distinguish these conditions from HIV-DSPN.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV-antiretroviral toxics neuropathy (HIV-ATN)
         </strong>
         – HIV-ATN is caused by older nucleoside reverse transcriptase inhibitors such as
         <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">
          stavudine
         </a>
         (d4T),
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         (ddI), and zalcitabine (ddC); the presumed mechanism of HIV-ATN is thought to be inhibition of gamma-DNA polymerase, which is required for mitochondrial replication [
         <a href="#rid47">
          47,48
         </a>
         ]. The clinical presentation is similar to that of HIV-DSPN. It can be distinguished from HIV-DSPN by a history of recent exposure to the offending agent, faster onset of symptoms, and symptom resolution with discontinuation of the offending drug [
         <a href="#rid49">
          49
         </a>
         ]. However, a "coasting" phenomenon has also been described, with paradoxical worsening of neuropathic symptoms over a period of four to eight weeks after stopping the offending antiretroviral drug [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
         </strong>
         – AIDP, the demyelinating variant of Guillain-Barré Syndrome, can mimic the clinical features of HIV-DSPN. However, AIDP typically presents with rapidly progressive ascending weakness with areflexia, reaching a nadir within four weeks. Occasionally, it can be a manifestation of HIV seroconversion. NCS/EMG demonstrates a demyelinating neuropathy with slow conduction velocities, prolonged distal latency, and conduction block. (See
         <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">
          "Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic inflammatory demyelinating polyradiculopathy (CIDP)
         </strong>
         – CIDP can present in patients with long-standing HIV infection. It has a more indolent course (symptoms progress for &gt;8 weeks) that can mimic the slow progression of HIV-DSPN. However, CIDP typically presents with ascending weakness while HIV-DSPN presents primarily with sensory deficits. NCS/EMG demonstrates a demyelinating neuropathy with slow conduction velocities, prolonged distal latency, and conduction block. Cerebrospinal fluid (CSF) analysis in patients with HIV and CIDP can demonstrate a mild lymphocytic pleocytosis, although this can also be seen in any patient with HIV. HIV-DSPN is not associated with specific CSF abnormalities [
         <a href="#rid52">
          52,53
         </a>
         ]. CIDP can also be differentiated from HIV-DSPN by its robust response to corticosteroids in patients with HIV, whereas HIV-DSPN does not respond to corticosteroids [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">
          "Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progressive polyradiculopathy
         </strong>
         – Progressive polyradiculopathy in patients with HIV typically presents with rapidly progressive weakness and numbness of the lower extremities with areflexia and sphincter dysfunction. Magnetic resonance imaging of the lumbar spine with gadolinium may demonstrate contrast enhancement of the nerve roots. Since cytomegalovirus (CMV) is a common cause of progressive polyradiculopathy in patients with HIV, CSF CMV DNA by polymerase chain reaction (PCR) is often positive [
         <a href="#rid55">
          55,56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14149.html" rel="external">
          "Polyradiculopathy: Spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes", section on 'Polyradiculopathy in HIV and AIDS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mononeuritis multiplex
         </strong>
         – Mononeuritis multiplex in patients with HIV is most commonly caused by CMV infection. This presents with a stepwise, asymmetric weakness and numbness involving two or more peripheral nerves or nerve roots [
         <a href="#rid57">
          57-59
         </a>
         ]. In cases where HIV-DSPN and mononeuritis multiplex cannot be distinguished on clinical presentation and non-invasive tests, nerve biopsy may be necessary. Sural nerve biopsy may demonstrate CD8 lymphocytic infiltration, necrotizing vasculitis, endoneurial infiltrates, and axonal damage [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3750.html" rel="external">
          "AIDS-related cytomegalovirus neurologic disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14149.html" rel="external">
          "Polyradiculopathy: Spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes", section on 'Polyradiculopathy in HIV and AIDS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1144084337">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mainstay of treatment is antiretroviral therapy (ART) and pharmacologic and nonpharmacologic therapies for symptom management.
        </p>
        <p class="headingAnchor" id="H2394453302">
         <span class="h2">
          General measures
         </span>
        </p>
        <p class="headingAnchor" id="H113723708">
         <span class="h3">
          Correcting reversible risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV-DSPN often have comorbidities that predispose to peripheral neuropathy, including diabetes mellitus, substance use, psychiatric disorders, and other chronic pain disorders [
         <a href="#rid61">
          61,62
         </a>
         ]. Patients with HIV-DSPN are more than twice as likely to have other chronic pain disorders and more likely to have substance use and psychiatric disorders compared with patients with HIV without HIV-DSPN [
         <a href="#rid61">
          61
         </a>
         ]. Identifying and correcting these comorbidities can help alleviate symptoms and prevent further progression. Use of any medications with known neurotoxicity should be minimized  (
         <a class="graphic graphic_table graphicRef69751" href="/z/d/graphic/69751.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H536858510">
         <span class="h3">
          Role of antiviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         ART is recommended for all patients with HIV. It reduces the risk of DSPN and may help to improve painful symptoms and thermal/nociceptive function in patients with neuropathic symptoms [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
         In one prospective observational study, 49 patients with HIV (more than half with sensory abnormalities) were initiated on ART and followed for eight months [
         <a href="#rid64">
          64
         </a>
         ]. Patients who had an increase in the CD4 cell count after ART initiation had higher rates of symptom resolution compared with those who did not respond to ART.
        </p>
        <p class="headingAnchor" id="H894010619">
         <span class="h3">
          Exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         We encourage all patients who can to exercise regularly. Exercise has wide-ranging health benefits and is a basic component of a healthy lifestyle. Moderate intensity aerobic exercises and progressive-resistance exercises have also demonstrated improvement in quality of life and pain reduction in patients with HIV-DSPN [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2876563799">
         <span class="h3">
          Foot care and fall prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend that all patients with neuropathy routinely inspect their feet for any skin fissures, open lesions, and early signs of infection. As more patients with HIV age, prevalence of comorbidities along with the loss of proprioception from HIV-DSPN can lead to worsening balance and increased risk of falls. Clinicians should implement interventions to minimize fall risk and counsel patients on precautions they can take to minimize falls in their daily life. (See
         <a class="medical medical_review" href="/z/d/html/3014.html" rel="external">
          "Falls: Prevention in community-dwelling older persons", section on 'Preventing falls'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H880982643">
         <span class="h2">
          Management of symptoms
         </span>
        </p>
        <p class="headingAnchor" id="H1635749667">
         <span class="h3">
          Goals of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no disease-modifying therapies for HIV-DSPN. The main goal of pharmacotherapy is to maximize symptom control using as few agents as possible with the least amount of side effects. Patients should be counseled that medications can only help reduce the 'positive' symptoms, such as pain and dysesthesias; they have no effect on 'negative' symptoms, such as numbness.
        </p>
        <p>
         Medications with demonstrated improvement of HIV-DSPN symptoms are scarce. Medications that have demonstrated significant pain reduction in other types of neuropathies, such as diabetic neuropathy, have not demonstrated the same success with HIV-DSPN [
         <a href="#rid67">
          67
         </a>
         ]. This may be due to either different pain mechanisms or to the high placebo response in these studies [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p>
         Access to certain therapies may be limited by cost. In the United States for example, there are no US Food and Drug Administration (FDA)-approved therapies for HIV-DSPN; thus, the agents are used off-label and may not be covered by insurers.
        </p>
        <p class="headingAnchor" id="H3811724625">
         <span class="h3">
          Initial therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3684142554">
         <span class="h4">
          Considerations in selecting treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         or
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         are our preferred first-line agents for most individuals. Selection between gabapentin and pregabalin is based on drug availability, cost, and provider and patient preference. In some cases, underlying comorbidities may inform drug selection, particularly if second drugs are needed for suboptimal response. As an example, antidepressants that may have beneficial effects on neuropathy (eg,
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         or tricyclic antidepressants) may be more appropriate in individuals with comorbid depression. If the patient also has insomnia, agents that have sedating effects, such as gabapentin, pregabalin, or the tricyclic antidepressants, can be useful. However, if there is autonomic dysfunction, tricyclic antidepressants should be avoided  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H124120100">
         <span class="h4">
          Gabapentin or pregabalin for most patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients without depression, we recommend initial therapy with
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         . This recommendation is in agreement with the HIV Medicine Association (HIVMA) guidelines for the management of chronic pain in patients living with HIV [
         <a href="#rid70">
          70
         </a>
         ].
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          Pregabalin
         </a>
         is a reasonable alternative if the patient cannot tolerate gabapentin  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         We generally start:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         at 100 to 300 mg one to three times daily and increase the dose weekly until symptoms resolve or we reach the maximum dose of 800 mg three times daily (2400 mg daily in two or three divided doses).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          Pregabalin
         </a>
         at 25 to 75 mg two times daily and increase to 75 to 200 mg two times daily if there is no response after several weeks.
        </p>
        <p>
        </p>
        <p>
         Side effects of
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         and
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         include somnolence, dizziness, ataxia, weight gain, and distal edema.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         is the main medication that has demonstrated efficacy in reducing symptoms due to HIV-DSPN. As an example, in a double-blind randomized study of 26 symptomatic patients with HIV-associated sensory neuropathies, gabapentin was more effective in reducing pain and improving sleep compared with placebo (44 versus 30 percent reduction in the median pain score from baseline) [
         <a href="#rid71">
          71
         </a>
         ]. Somnolence was reported in 80 percent of patients who received gabapentin; however, only one patient discontinued gabapentin due to adverse effects.
        </p>
        <p class="headingAnchor" id="H2679456781">
         <span class="h4">
          Patients with depression
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with depression, we suggest
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         as the initial therapeutic agent as it can help alleviate symptoms of depression in addition to those of HIV-DSPN. Tricyclic antidepressants are an alternative for such patients but are associated with more side effects and should not be used in individuals with autonomic dysfunction. For patients who are taking other antidepressants (eg, selective serotonin reuptake inhibitors), we discuss with the patient about switching to an agent with both antidepressant and analgesic effects (eg, duloxetine)  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duloxetine
         </strong>
         −
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          Duloxetine
         </a>
         should be initiated at 30 to 60 mg daily and can be titrated up to 120 mg daily. Side effects of duloxetine include somnolence, headaches, sexual dysfunction, nausea, vomiting, and hepatocellular hepatitis. Patients should be counseled to take the medication on a full stomach to minimize nausea. Duloxetine should not be combined with other serotonin or norepinephrine reuptake inhibitors (including tricyclic antidepressants) because these combinations can increase the risk of serotonin syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data on the efficacy of
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         are largely based on its effectiveness in other neuropathic pain syndromes, as studies assessing duloxetine in HIV-DSPN have not shown the same benefit [
         <a href="#rid72">
          72,73
         </a>
         ]. In a randomized study of 15 patients with HIV-DSPN, duloxetine did not demonstrate a significant change in pain intensity compared with placebo [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tricyclic antidepressants
         </strong>
         − Tricyclic antidepressants such as
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         or
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         should be started at 10 mg orally at bedtime and titrated up to 75 to 100 mg orally at bedtime. Side effects include dizziness, drowsiness, confusion, constipation, urinary retention, blurred vision, and cardiac arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data on the efficacy of tricyclic antidepressants are largely based on their effectiveness in other neuropathic pain syndromes, as studies assessing these agents in HIV-DSPN have not shown the same benefit [
         <a href="#rid73">
          73
         </a>
         ]. The tricyclic antidepressants,
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         or
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , were not found to be more beneficial than placebo in patients with HIV-DSPN [
         <a href="#rid75">
          75-77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3796774094">
         <span class="h4">
          Patients who want to avoid systemic medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Effective options are limited for such patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical therapy
         </strong>
         − The concept of topical therapy is attractive, but options are either difficult to access or do not have demonstrated efficacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          Capsaicin
         </a>
         <strong>
          patch
         </strong>
         − The high-concentration (8%) capsaicin dermal patch (NGX-010) is effective, however, challenges with administration limit accessibility. It is applied for 30 minutes every three months (not more frequently) but requires administration in the clinical setting and may require pretreatment with topical
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         due to a local burning sensation. In one study, a single, 30-minute application of the high-concentration (8%) capsaicin dermal patch provided 12 weeks of pain reduction compared with low-concentration capsaicin  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         <strong>
          patch
         </strong>
         – Lidocaine patch (5%) is used to treat neuropathic pain related to other diseases (eg, diabetic neuropathy). Up to three patches can be applied in a single 24-hour application period, for up to 12 hours. This should be followed up by a patch-free period for at least the next 12 hours. Data on efficacy of lidocaine patches for HIV-DSPN are limited; lidocaine patches have shown modest improvement in pain scores in patients with diabetic neuropathy [
         <a href="#rid79">
          79
         </a>
         ] and postherpetic neuralgia [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other topical agents such as low-dose
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         (0.075%) cream and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         gel have not been shown to be effective [
         <a href="#rid81">
          81,82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reasonable nonpharmacologic options for interested patients include acupuncture, hypnotherapy, and cannabis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acupuncture
         </strong>
         − The efficacy of acupuncture in reducing symptoms is unclear. In a randomized study of 50 patients with HIV, acupuncture with moxibustion (burning of mugwort leaf) reduced neuropathy symptoms compared with placebo [
         <a href="#rid83">
          83
         </a>
         ]. However, a larger, multicenter randomized study of 250 patients with HIV demonstrated no difference in symptom reduction between acupuncture and placebo [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypnotherapy
         </strong>
         − Hypnotherapy was found to improve quality of life and reduce pain in patients with HIV-DSPN [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medical and smoked cannabis
         </strong>
         − Medical or smoked cannabis may be a beneficial treatment in appropriate patients. Since
         <a class="drug drug_general" data-topicid="134930" href="/z/d/drug information/134930.html" rel="external">
          medical cannabis
         </a>
         does not have some of the risks of smoked cannabis, it may be a good initial option. For patients interested in smoked cannabis, risks and benefits should be weighed including the harmful effects of smoked cannabis in patients with underlying lung disease, adverse psychoactive effects, and abuse risk. Smoked cannabis was found to be effective in reducing symptoms, improving mood, and improving daily functioning in patients with HIV-DSPN in two randomized trials [
         <a href="#rid85">
          85,86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3161105978">
         <span class="h3">
          Follow-up
         </span>
        </p>
        <p class="headingAnchor" id="H3801085963">
         <span class="h4">
          Assessing response
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally assess for a response every few weeks during titration of medication dosages and then in one to three months after the patient has been on a stable dose of a therapeutic agent and/or undergone a trial of non-pharmacologic interventions. Additionally, we make sure any reversible risk factors have been corrected prior to assessing response to treatment.
        </p>
        <p class="headingAnchor" id="H2300798269">
         <span class="h4">
          Approach to patients with refractory symptoms
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In individuals with partial response to initial therapy
         </strong>
         − In a patient who has had a partial response to initial therapy, we suggest the addition of a second agent with a different mechanism of action  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, for a patient with partial response to
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , we typically add
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         ; a tricyclic antidepressant is an alternative second agent to add if duloxetine is not well tolerated or cost prohibitive. If duloxetine was initiated as the first agent, gabapentin or
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         should be selected as a second agent unless there is a contraindication. Dosing of and support for these medications is discussed elsewhere. (See
         <a class="local">
          'Gabapentin or pregabalin for most patients'
         </a>
         above and
         <a class="local">
          'Patients with depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In individuals with no response to initial therapy
         </strong>
         − In a patient who has had no response to initial therapy, we suggest switching to another agent  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who cannot take or have limited response to
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         , and/or tricyclic antidepressants,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         is a potentially effective option. Lamotrigine was found to be effective for HIV-DSPN in patients receiving neurotoxic ART, however, further studies in the era of effective ART are needed [
         <a href="#rid87">
          87
         </a>
         ]. We generally administer 200 to 400 mg daily. Lamotrigine should be avoided in patients with heart disease, as it can increase the risk of arrhythmias [
         <a href="#rid88">
          88
         </a>
         ]. Other side effects include dizziness, drowsiness, insomnia, skin rash, nausea, peripheral edema.
        </p>
        <p>
        </p>
        <p>
         Nonsystemic approaches (topical therapies, acupuncture) are potential adjunctive options of variable efficacy. (See
         <a class="local">
          'Patients who want to avoid systemic medications'
         </a>
         above.)
        </p>
        <p>
         Although we do not routinely recommend alpha-lipoic acid (ALA) or acetyl-L-carnitine for HIV-DSPN due to lack of efficacy data and/or the extensive adverse effects associated with the therapy, they may be tried in patients with refractory symptoms or in patients who are intolerant or have contraindications to preferred therapies.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha lipoic acid
         </strong>
         − The HIVMA guidelines for the management of chronic pain in patients living with HIV recommends ALA for HIV-DSPN with difficult-to-treat neuropathic pain [
         <a href="#rid70">
          70
         </a>
         ]. This is largely based on literature in diabetic neuropathy, as it has not been assessed in HIV-DSPN. (See
         <a class="medical medical_review" href="/z/d/html/5280.html" rel="external">
          "Management of diabetic neuropathy", section on 'Possibly effective'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acetyl-L-carnitine
         </strong>
         − Acetyl-L-carnitine, when given intramuscularly, reduced pain ratings when compared with placebo [
         <a href="#rid89">
          89
         </a>
         ]. An open-label single-arm study also improved pain scores, although intraepidermal nerve fiber density (IENFD) was not changed [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2340109477">
         <span class="h3">
          Limited role of opioid analgesics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic use of opioids should be avoided when possible. Opioids may be considered for breakthrough pain in select cases when patients do not respond to other therapies. We favor
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         as the opioid of choice in moderate to severe refractory chronic pain when the potential benefits outweigh harm  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         In patients for whom opioids are prescribed for chronic pain, we recommend storing controlled substances away from individuals at risk of misuse and/or overdose, educating patients about avoiding adverse events related to pharmacologic interactions, and educating the patient and family about signs of overdose and use of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         to reverse overdose [
         <a href="#rid70">
          70
         </a>
         ]. These recommendations are in line with the HIVMA guidelines for the management of chronic pain in patients living with HIV. (See
         <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">
          "Use of opioids in the management of chronic non-cancer pain"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3678053252">
         <span class="h3">
          Pharmacologic agents with unclear benefit
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following agents have not been shown to be more effective than placebo in reducing neuropathic symptoms.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurotrophic agents
         </strong>
         − A study of recombinant human nerve growth factor demonstrated that it was well tolerated and significantly improved pain symptoms but did not reduce neuropathy severity by neurologic exam, IENFD, or quantitative sensory testing [
         <a href="#rid91">
          91
         </a>
         ]. Another study demonstrated no significant treatment effect on nerve regeneration or collateral sprouting of nerve fibers on punch skin biopsies [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peptide T
         </strong>
         − Peptide T demonstrated small success in helping to relieve neuropathic pain in a phase I study [
         <a href="#rid93">
          93
         </a>
         ], although a double-blind, randomized multicenter study showed no significant difference between Peptide T and placebo [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prosaptide
         </strong>
         − While safe, prosaptide was ineffective at reducing neuropathic pain in HIV-DSPN [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1814212749">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition, prevalence, and risk factors
         </strong>
         − Distal symmetric polyneuropathy (DSPN) is the most common peripheral nervous system manifestation in patients with human immunodeficiency virus (HIV). Risk factors include uncontrolled HIV, older antiretroviral therapy regimens, older age, diabetes mellitus, triglyceridemia, statin use, substance use, and taller stature. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical symptoms
         </strong>
         − HIV-associated DSPN (HIV-DSPN) commonly presents with bilateral tingling, numbness, and burning that start distally in the toes and progress proximally. Other symptoms and signs suggestive of HIV-DSPN include imbalance and presence of autonomic dysfunction (eg, dizziness or fainting upon standing, urinary retention or incontinence). Symptoms generally progress gradually over the course of several weeks to months. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Exam findings
         </strong>
         − Neurologic exam findings include a reduction in pinprick, light touch, vibration, and temperature sensation in a stocking-glove distribution, as well as absent or reduced ankle reflexes. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establishing the diagnosis
         </strong>
         − A typical clinical presentation of a distal sensory neuropathy and exclusion of other causes of peripheral neuropathy  (
         <a class="graphic graphic_table graphicRef69751" href="/z/d/graphic/69751.html" rel="external">
          table 1
         </a>
         ) in a patient with HIV is sufficient to establish the diagnosis. There are no specific laboratory features associated with HIV-DSPN. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         − Differential diagnosis of HIV-DSPN includes HIV-antiretroviral toxic neuropathy, acute inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, progressive polyradiculopathy, and mononeuritis multiplex. (See
         <a class="local">
          'Differential Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General measures
         </strong>
         – All patients diagnosed with HIV-DSPN should undergo correction or optimization of all reversible risk factors (eg, uncontrolled HIV, diabetes mellitus, vitamin B12 deficiency, substance abuse). Patients should also be counseled to regularly exercise and examine their feet for any skin fissures, open lesions, and early signs of infection. (See
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial pharmacologic therapy for symptomatic patients
         </strong>
         – For symptomatic patients without depression, we suggest
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         or
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), as it has been shown to reduce symptoms. For patients with depression, we suggest
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         or tricyclic antidepressants. For patients who are taking other antidepressants (eg, selective serotonin receptor inhibitors), we discuss with the patient about switching to an agent with both antidepressant and analgesic effects (eg, duloxetine)  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Goals of treatment'
         </a>
         above and
         <a class="local">
          'Initial therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5280.html" rel="external">
          "Management of diabetic neuropathy", section on 'Initial pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative therapeutic options
         </strong>
         – Effective non-pharmacologic options, for those who are interested, include the high-concentration (8%)
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         dermal patch (NGX-010), acupuncture, hypnotherapy, and cannabis. (See
         <a class="local">
          'Patients who want to avoid systemic medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessing response
         </strong>
         − We generally assess for a response every few weeks during titration of medication dosages and then one to three months after the patient has been on a stable dose of a therapeutic agent and/or undergone a trial of non-pharmacologic interventions. (See
         <a class="local">
          'Assessing response'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory symptoms
         </strong>
         − Management of refractory symptoms includes adding a second agent in those with partial response or switching to an alternative in those with no response  (
         <a class="graphic graphic_table graphicRef138451" href="/z/d/graphic/138451.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Approach to patients with refractory symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999; 56:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh S, Chandran A, Jansen JP. Epidemiology of HIV-related neuropathy: a systematic literature review. AIDS Res Hum Retroviruses 2012; 28:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Julian T, Rekatsina M, Shafique F, Zis P. Human immunodeficiency virus-related peripheral neuropathy: A systematic review and meta-analysis. Eur J Neurol 2021; 28:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barohn RJ, Gronseth GS, LeForce BR, et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol 1993; 50:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma S, Estanislao L, Mintz L, Simpson D. Controlling Neuropathic Pain in HIV. Curr Infect Dis Rep 2004; 6:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Kitch D, Evans SR, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006; 66:1679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherry CL, Skolasky RL, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006; 66:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson-Papp J, Gonzalez-Duarte A, Simpson DM, et al. The roles of ethnicity and antiretrovirals in HIV-associated polyneuropathy: a pilot study. J Acquir Immune Defic Syndr 2009; 51:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 61:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anziska Y, Helzner EP, Crystal H, et al. The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. J Neurol Sci 2012; 315:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee S, McCutchan JA, Ances BM, et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. AIDS 2011; 25:F1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benevides MLACSE, Filho SB, Debona R, et al. Prevalence of Peripheral Neuropathy and associated factors in HIV-infected patients. J Neurol Sci 2017; 375:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010; 67:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011; 25:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Clifford DB, Deng L, et al. Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. J Neurovirol 2013; 19:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson-Papp J, Gelman BB, Grant I, et al. Substance abuse increases the risk of neuropathy in an HIV-infected cohort. Muscle Nerve 2012; 45:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson-Papp J, Sharma S, Simpson DM, Morgello S. Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy. J Neurovirol 2013; 19:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de la Monte SM, Gabuzda DH, Ho DD, et al. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol 1988; 23:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology 2002; 58:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou L, Kitch DW, Evans SR, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology 2007; 68:2113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaunu MP, Ratinahirana H, Raphael M, et al. The spectrum of changes on 20 nerve biopsies in patients with HIV infection. Muscle Nerve 1989; 12:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999; 53:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuller GN, Jacobs JM, Guiloff RJ. Nature and incidence of peripheral nerve syndromes in HIV infection. J Neurol Neurosurg Psychiatry 1993; 56:372.
          </a>
         </li>
         <li class="breakAll">
          Jazebi N, Evans C, Kadaru H, et al. HIV-Related Neuropathy: Pathophysiology, Treatment and Challenges. J Neurol Exp Neurosci 2021; 7:15.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinley FJ Jr, Pardo CA, Verma A. Human immunodeficiency virus and the peripheral nervous system workshop. Arch Neurol 2001; 58:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hao S. The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain. Curr Neuropharmacol 2013; 11:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apostolski S, McAlarney T, Hays AP, Latov N. Complement dependent cytotoxicity of sensory ganglion neurons mediated by the gp120 glycoprotein of HIV-1. Immunol Invest 1994; 23:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keswani SC, Polley M, Pardo CA, et al. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003; 54:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Datta G, Miller NM, Afghah Z, et al. HIV-1 gp120 Promotes Lysosomal Exocytosis in Human Schwann Cells. Front Cell Neurosci 2019; 13:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzuto N, Cavallaro T, Monaco S, et al. Role of HIV in the pathogenesis of distal symmetrical peripheral neuropathy. Acta Neuropathol 1995; 90:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace VC, Blackbeard J, Pheby T, et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain 2007; 133:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehmann HC, Chen W, Borzan J, et al. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Ann Neurol 2011; 69:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 2005; 19:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canter JA, Haas DW, Kallianpur AR, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J 2008; 8:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn K, Triolo A, Hauer P, et al. Impaired reinnervation in HIV infection following experimental denervation. Neurology 2007; 68:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall CD, Snyder CR, Messenheimer JA, et al. Peripheral neuropathy in a cohort of human immunodeficiency virus-infected patients. Incidence and relationship to other nervous system dysfunction. Arch Neurol 1991; 48:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schifitto G, McDermott MP, McArthur JC, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005; 64:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulevich SJ, Kalmijn JA, Thal LJ, et al. Sensory testing in human immunodeficiency virus type 1-infected men. HIV Neurobehavioral Research Center Group. Arch Neurol 1992; 49:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas S, Ajroud-Driss S, Dimachkie MM, et al. Peripheral Neuropathy Research Registry: A prospective cohort. J Peripher Nerv Syst 2019; 24:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winer JB, Bang B, Clarke JR, et al. A study of neuropathy in HIV infection. Q J Med 1992; 83:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouhassira D, Attal N, Willer JC, Brasseur L. Painful and painless peripheral sensory neuropathies due to HIV infection: a comparison using quantitative sensory evaluation. Pain 1999; 80:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obermann M, Katsarava Z, Esser S, et al. Correlation of epidermal nerve fiber density with pain-related evoked potentials in HIV neuropathy. Pain 2008; 138:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrmann DN, McDermott MP, Henderson D, et al. Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathy. Muscle Nerve 2004; 29:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roda RH, Bargiela D, Chen W, et al. Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy. Neurology 2021; 97:e156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kieburtz KD, Seidlin M, Lambert JS, et al. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J Acquir Immune Defic Syndr 1992; 5:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger AR, Arezzo JC, Schaumburg HH, et al. 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993; 43:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall DW, Brey RL, Cahill WT, et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988; 45:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisslén M, Chiodi F, Fuchs D, et al. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis 1994; 26:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moodley K, Bill PL, Patel VB. A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients. Neurol Neuroimmunol Neuroinflamm 2017; 4:e315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RF, Fox JD, Thomas P, et al. Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients. J Neurol Neurosurg Psychiatry 1996; 61:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bazan C 3rd, Jackson C, Jinkins JR, Barohn RJ. Gadolinium-enhanced MRI in a case of cytomegalovirus polyradiculopathy. Neurology 1991; 41:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson-Papp J, Simpson DM. Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 2009; 40:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis 1995; 20:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palma P, Costa A, Duro R, et al. Mononeuritis multiplex: an uncommon neurological manifestation of cytomegalovirus reactivation in an HIV-infected patient. BMC Infect Dis 2018; 18:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC, Pezeshkpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988; 23 Suppl:S38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navis A, Jiao J, George MC, et al. Comorbid Pain Syndromes in HIV-Associated Peripheral Neuropathy. Pain Med 2018; 19:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillay P, Wadley AL, Cherry CL, et al. Psychological Factors Associated With Painful Versus Non-Painful HIV-Associated Sensory Neuropathy. AIDS Behav 2018; 22:1584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centner CM, Little F, Van Der Watt JJ, et al. Evolution of sensory neuropathy after initiation of antiretroviral therapy. Muscle Nerve 2018; 57:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin C, Solders G, Sönnerborg A, Hansson P. Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000; 54:2120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maharaj SS, Yakasai AM. Does a Rehabilitation Program of Aerobic and Progressive Resisted Exercises Influence HIV-Induced Distal Neuropathic Pain? Am J Phys Med Rehabil 2018; 97:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mkandla K, Myezwa H, Musenge E. The effects of progressive-resisted exercises on muscle strength and health-related quality of life in persons with HIV-related poly-neuropathy in Zimbabwe. AIDS Care 2016; 28:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Schifitto G, Clifford DB, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010; 74:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Rice AS, Emir B, et al. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain 2014; 155:1943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruce RD, Merlin J, Lum PJ, et al. 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV. Clin Infect Dis 2017; 65:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn K, Arendt G, Braun JS, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004; 251:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; :CD007115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison T, Miyahara S, Lee A, et al. Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies. Pain Med 2013; 14:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998; 280:1590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinat N, Marinda E, Moch S, et al. Randomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory Neuropathy. PLoS One 2015; 10:e0126297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 51:1682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70:2305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev 2014; :CD010958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paice JA, Ferrans CE, Lashley FR, et al. Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 2000; 19:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estanislao L, Carter K, McArthur J, et al. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 2004; 37:1584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anastasi JK, Capili B, McMahon DJ, Scully C. Acu/Moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study. J Assoc Nurses AIDS Care 2013; 24:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorfman D, George MC, Schnur J, et al. Hypnosis for treatment of HIV neuropathic pain: a preliminary report. Pain Med 2013; 14:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003; 60:1508.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Lamictal (lamotrigine): Drug Safety Communication - Studies Show Increased Risk of Heart Rhythm Problems in Patients with Heart Disease. https://www.fda.gov/safety/medical-product-safety-information/lamictal-lamotrigine-drug-safety-communication-studies-show-increased-risk-heart-rhythm-problems (Accessed on April 19, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youle M, Osio M, ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007; 8:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valcour V, Yeh TM, Bartt R, et al. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Med 2009; 10:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schifitto G, Yiannoutsos C, Simpson DM, et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001; 57:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McArthur JC, Yiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000; 54:1080.
          </a>
         </li>
         <li class="breakAll">
          MacFadden D, Doob P. Role of peptide T in palliation of HIV-1 related painful peripheral neuropathy. 7th Intl AIDS Conference. Florence, Italy 1991.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 1996; 47:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans SR, Simpson DM, Kitch DW, et al. A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One 2007; 2:e551.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3711 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9923765" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21902585" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Epidemiology of HIV-related neuropathy: a systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33226721" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Human immunodeficiency virus-related peripheral neuropathy: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10025796" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8381649" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15142488" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Controlling Neuropathic Pain in HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16769940" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : HIV neuropathy natural history cohort study: assessment measures and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16567704" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19521250" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The roles of ethnicity and antiretrovirals in HIV-associated polyneuropathy: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15096404" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22123155" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21150557" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28320159" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence of Peripheral Neuropathy and associated factors in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7749792" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20457954" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21330902" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Peripheral neuropathy in HIV: prevalence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24297499" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431078" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Substance abuse increases the risk of neuropathy in an HIV-infected cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23580249" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2839106" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Peripheral neuropathy in the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11781415" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17562831" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2542787" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The spectrum of changes on 20 nerve biopsies in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10563609" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Total neuropathy score: validation and reliability study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8387098" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Nature and incidence of peripheral nerve syndromes in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8387098" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Nature and incidence of peripheral nerve syndromes in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11594913" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Human immunodeficiency virus and the peripheral nervous system workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24403874" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8144198" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Complement dependent cytotoxicity of sensory ganglion neurons mediated by the gp120 glycoprotein of HIV-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12953261" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31379513" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : HIV-1 gp120 Promotes Lysosomal Exocytosis in Human Schwann Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8525797" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Role of HIV in the pathogenesis of distal symmetrical peripheral neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17433546" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21280080" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16103764" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17684475" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17438214" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Impaired reinnervation in HIV infection following experimental denervation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1668978" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Peripheral neuropathy in a cohort of human immunodeficiency virus-infected patients. Incidence and relationship to other nervous system dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15753420" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Markers of immune activation and viral load in HIV-associated sensory neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1360202" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Sensory testing in human immunodeficiency virus type 1-infected men. HIV Neurobehavioral Research Center Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30629307" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Peripheral Neuropathy Research Registry: A prospective cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1448548" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A study of neuropathy in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10204739" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Painful and painless peripheral sensory neuropathies due to HIV infection: a comparison using quantitative sensory evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18096318" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Correlation of epidermal nerve fiber density with pain-related evoked potentials in HIV neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14981742" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33947785" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7585087" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Mitochondrial toxicity of antiviral drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11526116" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9880091" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1346633" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8382349" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2970837" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7855550" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28054000" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8937337" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1653916" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Gadolinium-enhanced MRI in a case of cytomegalovirus polyradiculopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19771594" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Neuromuscular diseases associated with HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795068" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cytomegalovirus infections of the nervous system in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30419847" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Mononeuritis multiplex: an uncommon neurological manifestation of cytomegalovirus reactivation in an HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2831801" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Neuromuscular diseases associated with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29024980" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Comorbid Pain Syndromes in HIV-Associated Peripheral Neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28710709" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Psychological Factors Associated With Painful Versus Non-Painful HIV-Associated Sensory Neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28561925" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Evolution of sensory neuropathy after initiation of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10851375" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29189306" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Does a Rehabilitation Program of Aerobic and Progressive Resisted Exercises Influence HIV-Induced Distal Neuropathic Pain?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26729347" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The effects of progressive-resisted exercises on muscle strength and health-related quality of life in persons with HIV-related poly-neuropathy in Zimbabwe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20402746" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124207" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24907403" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29020263" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15503108" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24385423" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25575710" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23565581" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9820261" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25974287" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Randomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory Neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9855523" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18541884" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15210530" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25058164" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Topical lidocaine for neuropathic pain in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10687326" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Topical capsaicin in the management of HIV-associated peripheral neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15577414" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23582399" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Acu/Moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23566167" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Hypnosis for treatment of HIV neuropathic pain: a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296917" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18688212" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12743240" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12743240" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17461852" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19200173" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11591856" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10720278" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10720278" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8909439" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17653259" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
